A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer

Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer

(2016) Stacey M Stein et al.   BRITISH JOURNAL OF CANCER

Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer

(2015) Masahiro Nozawa et al.   International Journal of Clinical Oncology

Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy

(2015) Yoshimasa Kosaka et al.   SUPPORTIVE CARE IN CANCER

Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer

(2014) Takuji Okusaka et al.   CANCER SCIENCE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma

(2013) Hemchandra Mahaseth et al.   PANCREAS

A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor UGT1A1*1/*1,*1/*6 or *1/*28

(2012) Yu Sunakawa et al.   ONCOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

(2010) Johann Sebastian de Bono et al.   LANCET